Position of Cladribine Tablets in Managing RRMS
Published on Fri, 23 Apr 2021

Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates
This expert narrative review outlines the practical use of cladribine tablets for managing highly active relapsing-remitting multiple sclerosis (RRMS). As an immune reconstitution therapy (IRT), cladribine tablets offer prolonged relapse-free periods with minimal monitoring. They are recommended for patients with highly active MS, poor adherence to continuous therapies, treatment-naïve cases with high disease activity, or those planning a family. The treatment has shown no adverse interaction with COVID-19 infections, and robust immune responses to vaccines have been observed, supporting safe COVID-19 vaccination during therapy.